Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 1, 2013OncoTargets and TherapyOpen Access

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes

View Full Paper
Ask AI
Bookmark
Share

Authors

Srđan Verstovšek
Srđan VerstovšekUppsala UniversityJGJason GotlibOntario Institute for Cancer ResearchVGVikas GuptaSher-e-Kashmir University of Agricultural Sciences and Technology of Jammu

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Verstovšek et al. (2013) studied this question.

synapsesocial.com/papers/6a104ea010ed65f1d0fca4d6https://doi.org/10.2147/ott.s53348
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Jak-Stat pathway in normal and perturbed hematopoiesis2000 · 296 citations
  2. 2A New Prognostic Scoring System for Primary Myelofibrosis Based on a Study of the International Working Group for Myelofibrosis Research and Treatment2008 · 108 citations
  3. 3Efficacy, Hematologic Effects, and Dose of Ruxolitinib in Myelofibrosis Patients with Low Starting Platelet Counts (50–100 × 109/L): A Comparison to Patients with Normal or High Starting Platelet Counts2012 · 14 citations
  4. 4Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF)2012 · 57 citations
  5. 5Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I2015 · 335 citations